NervGen Pharma
NervGen Pharma is a clinical-stage biopharmaceutical company developing NVG-291, a first-in-class neuroreparative peptide targeting the CSPG-PTPσ pathway to enable nervous system repair, with lead Phase 3 program in chronic spinal cord injury and pipeline expansion into MS, Alzheimer's, TBI, and peripheral nerve injury.
- Company typePublic
- Founded2018
- HeadquartersVancouver, Canada
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What NervGen Pharma does
NervGen Pharma Corp. is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Vancouver, British Columbia, with shares trading on Nasdaq under the ticker NGEN since January 8, 2026 (following voluntary delisting from the TSX Venture Exchange on March 16, 2026). The company is purpose-built around a single therapeutic platform of neuroreparative peptides that target the inhibitory CSPG-PTPσ pathway to enable the central nervous system to repair itself. Its lead asset, NVG-291, is a first-in-class 35 amino acid peptide administered as a daily subcutaneous injection for 12 weeks, licensed exclusively worldwide from Case Western Reserve University based on foundational research by Dr. Jerry Silver. The Phase 1b/2a CONNECT SCI study in cervical motor incomplete spinal cord injury produced statistically significant and durable functional improvements — 100% responder rate (10/10) versus 10% placebo (1/10) on the Global Statistical Test (p=0.0001) — with benefits extending up to 364 days post-treatment in chronic patients up to 10 years post-injury.
NervGen's pipeline extends beyond NVG-291 to include the preclinical next-generation candidate NVG-300, the rodent analog NVG-291-R used in translational research, and indication expansion programs in multiple sclerosis (remyelination), Alzheimer's disease, stroke, traumatic brain injury (DoD/WRAIR-funded), traumatic hearing loss (DoD/59th Medical Wing-funded), and peripheral nerve injury (DoD-funded, up to $1.5M). The FDA has granted Fast Track designation for NVG-291 in SCI, with an EMA Orphan Drug designation, and a successful End-of-Phase 2 meeting in April 2026 aligned the FDA on the Phase 3 RESTORE registrational study design in chronic tetraplegia (~150 subjects across U.S. and Canadian sites, initiating mid-2026).
The company is pre-revenue with no commercial product and no product pricing; Q1 2026 financials showed a $1.7 million net loss and $16.6 million cash position, with the TTM loss at $0.40 per share. Operations are funded by capital markets activity and government grants — cumulative disclosed funding exceeds $100 million, including a US$60 million underwritten public offering in May 2026 (joint bookrunners Leerink Partners and TD Cowen), a US$10 million non-brokered private placement in November 2025 (with PFP Biosciences increasing its stake to 18.8%, alongside SCI Ventures and the Paul and Phyllis Fireman Charitable Foundation), a US$15.2 million private placement in July 2022, and an $8 million bought deal in November 2021. Topline Phase 3 RESTORE data is targeted for the first half of 2028, and H.C. Wainwright maintains a Buy rating with a US$18 price target.
NervGen Pharma firmographics
Firmographics- Name
- NervGen Pharma
- Legal name
- NervGen Pharma Corp.
- Website
- https://nervgen.com
- Company type
- Public
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- NervGen Pharma is a clinical-stage biopharmaceutical company developing NVG-291, a first-in-class neuroreparative peptide targeting the CSPG-PTPσ pathway to enable nervous system repair, with lead Phase 3 program in chronic spinal cord injury and pipeline expansion into MS, Alzheimer's, TBI, and peripheral nerve injury.
- Ownership category
- akta.pro rank
NervGen Pharma industry classification
Industry- Product category
- Neuroreparative Biopharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industry
- Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)
Keywords
Where NervGen Pharma is headquartered
LocationHeadquarters
- HQ city
- Vancouver
- HQ country
- Canada
- HQ region
- North America
Offices2 records
Markets served
NervGen Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel
Revenue model
- Pre-revenue clinical-stage company: NervGen is a clinical-stage biopharmaceutical company with no product revenue. The company remains unprofitable with a loss of $0.40 per share over the trailing twelve months. All clinical development is funded by capital markets activity (private placements, public offerings, ATM equity program) and government grants. Future revenue is anticipated to come from commercialization of NVG-291, the first potential pharmacologic treatment for spinal cord injury, subject to FDA approval.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | — | Public equity offering pricing — not product pricing |
Go-to-market motion3 records
Distribution channels2 records
Marketing channels8 records
NervGen Pharma product offering
Product offeringCore offering
NervGen Pharma is a clinical-stage biopharmaceutical company developing NVG-291, a first-in-class 35 amino acid neuroreparative peptide administered by daily subcutaneous injection that targets the inhibitory CSPG-PTPσ pathway to enable the central nervous system to repair itself. Its lead program addresses chronic and subacute cervical motor incomplete spinal cord injury (SCI), with FDA Fast Track and EMA Orphan Drug designations; a planned Phase 3 RESTORE registrational study in chronic tetraplegia is targeted for mid-2026 across U.S. and Canadian sites. Pipeline expansion targets multiple sclerosis, Alzheimer's disease, traumatic brain injury, traumatic hearing loss, and peripheral nerve injury.
Product overview
NervGen Pharma is a clinical-stage biopharmaceutical company built around a single therapeutic platform of neuroreparative peptides that target the inhibitory CSPG-PTPσ pathway to enable the nervous system to repair itself. Its core asset is the lead peptide NVG-291, currently in the Phase 1b/2a CONNECT SCI Study for chronic and subacute spinal cord injury (with Fast Track designation from the FDA and Orphan Drug designation from the EMA) and advancing into the planned Phase 3 RESTORE registrational study. The next-generation candidate NVG-300 is being evaluated in preclinical models, while the rodent analog NVG-291-R is used in translational research across multiple neurological conditions. Preclinical work in traumatic brain injury and traumatic hearing loss is funded and conducted by the U.S. Department of Defense. Together, NVG-291 and NVG-300 form NervGen's portfolio pursuing a pharmacologic approach to transform the treatment paradigm for neurotraumatic and neurologic conditions.
Differentiator
Problem solved
Functional benefit
Brands
- NVG-291: Lead therapeutic candidate — a first-in-class subcutaneously administered neuroreparative peptide targeting the CSPG-PTPσ pathway for spinal cord injury and other neurologic conditions.
- NVG-300
- CONNECT SCI Study
- RESTORE
Products and services
- NVG-291 First-in-class 35 amino acid neuroreparative peptide administered by daily subcutaneous injection for 12 weeks, targeting the inhibitory CSPG-PTPσ pathway to enable the central nervous system to repair itself; lead therapeutic candidate for chronic and subacute cervical motor incomplete spinal cord injury, with FDA Fast Track designation and EMA Orphan Drug designation.
- NVG-300 Internally discovered next-generation peptide candidate being evaluated in preclinical models for neurotraumatic and neurologic conditions with significant unmet medical need, extending the NervGen platform beyond NVG-291.
Companies that use NervGen Pharma
Customer profileSegments4 records
Ideal customer profiles3 records
NervGen Pharma technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
NervGen Pharma partnerships and signals
Strategic signalPartnerships
Eight partnerships are on record, tiered core, flagship and minor.
- Leerink PartnerscoreActing as joint bookrunning manager for NervGen's May 2026 underwritten public offering of 24 million common shares at $2.50/share plus warrants, generating approximately $60 million gross proceeds. Also covers NervGen as an analyst. Provides underwriting and capital markets advisory services.
- TD CowencoreActing as joint bookrunning manager for NervGen's May 2026 underwritten public offering of $60 million. Also covers NervGen as an analyst (Joe Thome, PhD). Provides underwriting and capital markets advisory services.
- Case Western Reserve University (CWRU)flagshipNervGen was founded in 2018 following many conversations between Dr. Harold Punnett and Dr. Jerry Silver. NervGen holds exclusive worldwide rights to the intellectual property from CWRU covering NVG-291, the foundational therapeutic peptide. The technology is based on Dr. Silver's research identifying the inhibitory CSPG-PTPσ pathway and the discovery of NVG-291 in 2015 as a 35 amino acid peptide.
- Shirley Ryan AbilityLabcoreClinical trial site partner supporting the Phase 1b/2a CONNECT SCI Study. The company acknowledged the support and participation of the SCI community and the Shirley Ryan AbilityLab in the CONNECT SCI Study. Provides clinical research infrastructure for NVG-291 evaluation in chronic SCI patients.
- U.S. Department of Defense (Walter Reed Army Institute of Research / WRAIR)corePreclinical development for traumatic brain injury (TBI) funded and conducted by the U.S. Department of Defense via the Walter Reed Army Institute of Research (WRAIR). October 2022: NervGen received up to $1.5 million in DoD funding to evaluate NVG-291-R for peripheral nerve injury treatment, aimed at establishing preclinical proof-of-concept for nerve regeneration and recovery in military and civilian populations.
- U.S. Department of Defense (59th Medical Wing)minorPreclinical development for traumatic hearing loss funded and conducted by the U.S. Department of Defense via the 59th Medical Wing. Partnership extends NVG-291-R research into additional neurotraumatic indications relevant to military populations.
- Newton TechcoreAI-powered movement intelligence company specializing in video-based motion capture and computational analysis of standardized walking assessments. Newton Tech conducted the independent, blinded biomechanical gait analyses for the Phase 1b/2a CONNECT SCI study, producing quantitative measures of gait quality (coordination, mechanical effort, postural stability). Statistical methodology and computational analyses independently verified by the Department of Computational Biomedicine at a leading academic medical center.
- Russo PartnerscoreMedia relations firm handling media inquiries for NervGen. Contacts David Schull or Ignacio Guerrero-Ros, PhD at (858) 717-2310. Provides public relations and earned media support.
Scale indicators16 records
Recent moves7 records
Expansion highlights6 records
NervGen Pharma competitors and assessment
Company assessmentDirect peers
- BioAxone BioSciences: Clinical-stage biotech developing Cethrin (BA-2109), a rho inhibitor delivered locally for spinal cord injury repair. Most direct competitor to NervGen's NVG-291 in SCI with overlapping mechanism (targeting inhibitory environment) and similar clinical-stage positioning.
- Acorda Therapeutics: Commercial CNS company with Fampridine (Ampyra) approved for MS walking impairment. Direct peer in neurorehabilitation with SCI/MS patient overlap and commercial-stage CNS infrastructure NervGen lacks.
- Reata Pharmaceuticals: Was a CNS-focused biotech with Skyclarys approved for Friedreich's ataxia (a rare neurological disease with CNS repair mechanism). Acquired by Biogen for $7.3B in 2023 — provides M&A precedent for CNS-focused rare disease biotech with first/best-in-class mechanism and Fast Track designation. Comparable trajectory NervGen could follow.
Broad incumbents
- Scholar Rock: Late-stage biotech developing apitegromab for spinal muscular atrophy and other neuromuscular conditions. Comparable clinical-stage CNS/neuro company with Phase 3 readout dynamics and muscle function/recovery end-points similar to NVG-291's SCI program.
- Axsome Therapeutics: Commercial CNS company with Auvelity (dextromethorphan/bupropion) for major depressive disorder. Comparable mid-cap CNS company with similar sales force buildout challenges in specialty neurology and FDA Fast Track use precedent.
- Stoke Therapeutics: Clinical-stage antisense oligonucleotide company for genetic CNS disorders including Dravet syndrome. NervGen's Chief Regulatory Officer Shamim Ruff joined from Stoke; comparable clinical-stage CNS biotech with similar FDA regulatory pathway work.
Emerging players
- Kringle Pharma: Japan-based clinical-stage biotech developing hepatocyte growth factor (HGF) for spinal cord injury and ALS. Direct SCI indication overlap with NVG-291 and similar neuro-regenerative therapeutic approach; regional competitor with parallel SCI clinical program.
- ArmaGen: Clinical-stage biotech developing IgG fusion proteins that cross the blood-brain barrier to treat CNS disorders. Comparable CNS drug delivery and rare neurological disease focus; partnership/Bayer deal provides comparable BD precedent for CNS biotech.
- Passage Bio: Clinical-stage gene therapy company for rare CNS disorders including GM1 gangliosidosis and frontotemporal dementia. Comparable clinical-stage neuroscience biotech with similar capital-intensive development model and platform-based pipeline approach.
Regional players
- Helius Medical Technologies: Commercial-stage medical device company with Portable Neuromodulation Stimulator (PoNS) approved for MS gait deficit. Adjacent therapeutic area (neuroplasticity/recovery) with similar SCI/MS patient focus and specialty neurology channel; device rather than pharmacologic modality.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks7 records
Key highlights7 records
Customer concentration
NervGen Pharma social profiles
Digital presenceNervGen Pharma compliance and trust
Trust signalCompliance4 records
NervGen Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
NervGen Pharma leadership team
Management profileNumber of profiles
Profiles8 records
NervGen Pharma funding detail
Funding detailFunding overview
Funding rounds11 records
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NervGen Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NervGen Pharma
What does NervGen Pharma do?
NervGen Pharma is a clinical-stage biopharmaceutical company developing NVG-291, a first-in-class 35 amino acid neuroreparative peptide administered by daily subcutaneous injection that targets the inhibitory CSPG-PTPσ pathway to enable the central nervous system to repair itself. Its lead program addresses chronic and subacute cervical motor incomplete spinal cord injury (SCI), with FDA Fast Track and EMA Orphan Drug designations; a planned Phase 3 RESTORE registrational study in chronic tetraplegia is targeted for mid-2026 across U.S. and Canadian sites. Pipeline expansion targets multiple sclerosis, Alzheimer's disease, traumatic brain injury, traumatic hearing loss, and peripheral nerve injury.
Is NervGen Pharma a public or private company?
NervGen Pharma is a public company. It is classified as public and is currently operating.
When was NervGen Pharma founded?
NervGen Pharma was founded in 2018. It employs 11 to 50 people.
Where is NervGen Pharma based?
NervGen Pharma is headquartered in Vancouver, Canada, in the North America region.
How does NervGen Pharma make money?
One revenue line is on record: pre-revenue clinical-stage company.
Who are NervGen Pharma's main competitors?
Direct peers on record are BioAxone BioSciences, Acorda Therapeutics and Reata Pharmaceuticals. Broad incumbents are Scholar Rock, Axsome Therapeutics and Stoke Therapeutics. Emerging players are Kringle Pharma, ArmaGen and Passage Bio. Helius Medical Technologies is listed as a regional player.
Does NervGen Pharma have an API?
No public API is recorded for NervGen Pharma.
What industry is NervGen Pharma in?
NervGen Pharma's product category is Neuroreparative Biopharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies. Its NAICS code is 325412 and its SIC code is 2834.